Enhancing Neuromuscular Disorder Research with Wearable DHTs
Establishing clinical benefit is one of the most challenging and costly steps in developing new treatments for patients with neuromuscular disorders (NMD) such as amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). Symptoms of NMD can affect patients in many ways, including their physical activity, sleep, gait, and mobility.
With the advent of sensor-based digital health technologies (DHTs), we now have an unprecedented opportunity to remotely and continuously assess how study participants in NMD research function in their daily lives.
This digital endpoints guide provides information on wearable DHT adherence in NMD clinical trials, a list of digital endpoints available for NMD trials, and opportunities to advance NMD research with wearable DHTs, including
- Supporting patient-centric NMD drug development with easy-to-use wrist-worn technology
- Collecting previously inaccessible clinical insights for NMD trials through novel digital endpoints
- Passively examining physical activity, gait, upper limb mobility, sleep behavior, and vital signs in the patient’s natural environment
Advancing Validation of Digital Measures in NMD
Learn more about how Ametris is supporting and collaborating with leaders in the field of NMD research and clinical development to validate the analytical and clinical aspects of wearable-based measures in NMD: